SeraSeal is a new and innovative haemostatic agent designed to stop bleeding on contact and within seconds for arterial haemorrhages. It comprises agar and bovine factor proteins – II, VII, IX, and X and acts as a catalyst in the clot formation process. This patented single component system can tackle any bleeding situation with the potential to save many lives.
SeraSeal is the world’s only primary haemostatic agent that stops major haemorrhages in seconds, even in the presence of anticoagulant therapy or factor deficiencies, without the need for any of the traditional applications of pressure, elevation, tourniquets, or cauterization. SeraSeal can be applied by a syringe, spray, catheter, foam, trauma dressing, surgical sponge, bandage strip, and a swab.
All products are stable with long shelf lives that require no preparation. SeraSeal does not create chemical burns but rather accelerates healing for the patient. By contrast, all conventional products in the healthcare space are secondary haemostatic agents, effective only for minor bleeds. Generally, they require direct pressure cauterization, and some are limited to external use only.
Ajaypal Singh Randhawa, chief executive officer, Swasth Kare, is hopeful that this revolutionary product will give a definitive solution to the long-standing problem of doctors and surgeons. “By substantially reducing blood loss, whole blood units needed, and time in surgery, every stage of healthcare is significantly impacted. If we truly place patients’ lives at the forefront, we use SeraSeal to stop bleeding, whether in the hands of first responders or the surgical theatre. We save countless hours of clinical time, reduce post-operation pain management and preserve tissue. Patients, hospitals, medical professionals, ambulances, insurance companies, governments, and military troops benefit from this product, which saves both lives and costs.”
How will SeraSeal impact the operating rooms in clinical settings?
- SeraSeal is a primary haemostatic product, and it can be used in place of cauterization or in concert with cauterization
- It is effective on all forms of coagulopathy – anticoagulant drugs, platelet inhibitors, factor deficiency. SeraSeal is also effective with patients under anticoagulation therapy (Phenprocoumon/MarcumarR) or with coagulation factor deficiencies. Affected patients can continue their treatment with coagulation inhibitors.
- The benefits of SeraSeal offer cost avoidance and cost reductions by the following –
- Can be used in place of cauterization – There is no loss of tissue due to third-degree burns or adhesions. As a result, less pain medication is required, wounds heal faster, and hospital stay is shorter.
- Clinical studies show a 90% reduction of blood loss in 40% of surgical cases. Fewer transfusions reduce costs, potential transfusion complications, hospital stay, and strain on the blood supply.
- Reduces surgical time – Instead of cauterizing each individual bleed within a wound, SeraSeal as a liquid will arrest all the individual bleeds in one motion. In some surgical procedures, the collective time to haemostasis is reduced by 50%.
- Effective in all forms of coagulopathy – Patients on anticoagulant therapy can be maintained on their dosage levels during surgery, thereby significantly reducing their risk. In patients with a factor deficiency, a factor replacement before surgery is unnecessary.
Seraseal can be used effectively in all medical and surgical settings, major ones being Liver transplant, Kidney transplant, Heart transplant, Knee and Hip replacement surgeries, gynaecology and obstetrics/childbirth (Premature infants), Gastrointestinal surgery, Trauma, Hidden bleeds, Retractable vessels, Spine surgery, cosmetic and reconstructive surgery, Prostate surgery, Coagulopathy, and Haemophilia.
